Conexeu Sciences Inc. · NASDAQ:CNXU
Conexeu Sciences — Investor Presentation (2026)
26 slides from Conexeu Sciences's investor presentation, 2026
Slide 1: Architecting Bioregeneration
Architecting Bioregeneration Corporate Presentation (LEGAL) CONFIDENTIAL Not an offer to sell nor a solicitation NOT FOR DISTRIBUTION of an offer to buy any securities. Spring 2026 ARCHITECTING BIOREGENERATION
Slide 2: Cautionary Note on Forward Looking Information
CAUTIONARY NOTE ON Forward Looking FORWARD LOOKING INFORMATION Statement This Presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws (collectively,“ forward-looking information”) with respect to CONEXEU. Statements in thi
Slide 3: What if we could regenerate the tissue lost
What if we could regenerate the tissue lost to: Wounds/Burns Aging GLP-1 Gum Disease Cancer Resections **Preclinical concept; not predictive of clinical outcomes. CXU™ is an investigational device. ARCHITECTING BIOREGENERATION
Slide 4: CXU is a New ECM Platform Technology
CXU™ is a New ECM Changing Possibilities into Realities Platform Technology Restoring and generating native tissue, with the opportunity to elevate the standard of care across multiple potential markets 5 Current Markets Burns/Full- Wound Care Soft Tissue Injectables Thickness Tissue/Gums Scaffolds
Slide 5: Demonstrates a Unique Liquid to Gel Formulation
On application , CXU flows as a liquid Demonstrates a Unique Liquid to Flows through a 30G needle for precise placement2 Gel Formulation Approaching physiological A flowable, regenerative tissue temperatures matrix composed of collagen and (37°C), CXU natural proteins and sugars. undergoes rapid Eng
Slide 6: Architecting Regeneration in a Bottle: Ten-Minute Tissue
Architecting Regeneration in a Bottle Ten-Minute Tissue™ Shelf-stable, Scalable Format Works with Established Clinical Workflows Standard vial format, GMP-compatible Versatile delivery and user-friendly operation Lyophilized powder (ambient storage/no cold chain) Easy inventory + Reduced storage bur
Slide 7: CXU Development
CXU Development 10 Years Of International Patent Development Patents Assignment Developed over 10 years at the Patents Granted 100% Assignment to the University of British Columbia. right, title, and interest in and to the patents worldwide. Validated 11 Peer-reviewed Publications Technology Acta Bi
Slide 8: Meet the Architects of Bioregeneration
Meet the Architects of Bioregeneration Leadership Team Miles D. David R. Dr. Claudia Steve Harrison Bogart Chavez Inouye President & CEO Founder, Director M.D., Ph.D. Founder CFO & CSO Former President/GM of Galderma North Founded Conexeu Sciences. 25-years World-class tissue engineering scientist w
Slide 9: Tissue Regeneration Trilogy
Tissue Regeneration Trilogy The Science Tissue regeneration requires the coordinated presence of three essentials1: The primary drivers which The biochemical signals that The extracellular matrix generate new tissue regulate cell behavior provides structural and biochemical support All three must be
Slide 10: What Injury, Aging and Volume Loss Take Away
What Injury, Aging and Volume Loss Take Away Tissue Regeneration Requires a New ECM. Scaffold (ECM) Loss The structural framework that organizes MARKET NEED When the ECM is compromised, the biologic Regeneration is compromised. process shifts from regeneration to scar formation. Three conditions tha
Slide 11: The Incomplete Scaffold Standard
Wound Care Formats The Incomplete Scaffold Standard Lack of uniformity and functional ECM in existing treatments can hinder the healing process 1 Incomplete coverage + poor integration = variable healing and delayed closure Powdered Collagen Collagen Collagen Collagen Fillers Grafts Flowables Gels I
Slide 12: CXU Optimized for Tissue Integration
CXU™ Optimized for Tissue Integration Market Need A Conforming Scaffold That Fills Voids and Integrates in the Wound Ten Minute Tissue™ A complete, integrated coverage in wound geometry1 Flowable1 Gels In Place1 Designed For Contours to various Temperature sensitive, Better Integration 2 wound margi
Slide 13: CXU Filling the Gap in Tissue Regeneration
CXU™ Filling the Gap in Tissue Regeneration Function and Form 1 A Biomimetic ECM Scaffold Flowable 2 Limited Function ECM Limited ECM Format Flows into complex wound geometry (incl. 30G needle) Thermosensitive 2 Liquid-to-gel transition at body temp (~37°C) of FDA-cleared KGN of 43 cleared devices i
Slide 14: One Formula. One Device.
510(k) Predicate Predicate-Based Foundation The “One Formula” Advantage Strategy Advantage One Formula. One Device. • A cleared CXU device would be intended • CXU-B data package is designed to support Pre- to establish a safety profile and substantial Sub alignment with FDA (targeted Q1 2027). Pre-
Slide 15: What if we could regenerate the tissue lost to aging
What if we could regenerate the tissue lost to aging instead of just filling space?* *Preclinical concept; not predictive of clinical outcomes. CXU™ is an investigational device. ARCHITECTING BIOREGENERATION / 15
Slide 16: Market Problem: Safely Restoring the Extracellular Matrix
Market Problem: Safely Restoring the Extracellular Matrix Natural Aging GLP-1 Deflation Extracellular matrix (ECM) degradation plus soft tissue and bony volume loss Rapid, significant weight loss affects overall skin quality and function resulting in appearance of age1 depletes facial fat pads and b
Slide 17: GLP-1 Impact is exposing the real potential within Aesthetics
GLP-1 Impact is exposing the real potential within Aesthetics Market Size (Billion USD) 2.0B6 taking prescription weight global market 2023-20292 GLP-1 prescriptions loss medications1 forecasted by 20303 0.7B concerned with loose skin4 seeking facial aesthetic treating GLP-1 concerns2 procedures are
Slide 18: Market Challenge: Dermal Filler Technology is 20+yrs Old
Market Challenge: Dermal Filler Technology is 20+yrs Old 1 Current solutions fail to address body contouring and GLP-1 driven tissue loss Bellafill $11.0B Biostimulator 2 (PMMA) The last bio- Sculptra Radiesse stimulatory Biostimulator Biostimulator More HA Entrants, Line Extensions, New Indications
Slide 19: GLP-1 fueled demand
GLP-1sGLP-1s are creating a $2B a created knock-on economyeconomy $2B knock-on that today's— tools can't reach today's tools can't reach it N E W C A T E G O R Y P O T E N T I A L ▲ Large Volume BIOREGENERATION GLP-1 Demand $2.0B GLP-1 fueled demand → t ion NEW KNOCK-ON ECONOMY g ra i $700M → $2.0B
Slide 20: Designing a Next-Generation Injectable Matrix for Tissue Regeneration
Designing a Next- Designing A New Regenerative Platform1 Generation Injectable Mimics key properties of native extracellular matrix Matrix for Tissue to support tissue in-growth Promotes constructive tissue response with minimal inflammation Regeneration* Injectable, flowable, and conforming for pre
Slide 21: High Potential Utility for CXU
High Potential Utility for CXUTM Designing a new approach for injectable approach for tissue support in aesthetics to support to support tissue remodeling processes** A Regenerative injectable with the potential to become a category leader in medical aesthetics Natural tissue in-growth supported by
Slide 22: Meet the Architects of Bioregeneration
Meet the Architects of Bioregeneration Dr. Paul Sebastian Dr. Aaron Directors Lorenc Purcell Farberg MD, FACS, Director PhD, Director M.D., Director Dr. Lorenc is board certified by the American CEO and Chief Investment Officer of 1.2 Capital, Dr. Aaron Farberg is a double board-certified Board of P
Slide 23: Meet the Architects of Bioregeneration: Medical Advisors
Meet the Architects of Bioregeneration Medical Advisors Dr. Scott Dr. Peter Dr. Vijay Dr. Anthony Rineer Randelzhofer Gorantla Papp MD MPH FACEP MD, Dent. DGI, NvOI M.D., Ph.D. FRCS MD, PhD, FRCSC, Advisor FABA, Advisor Dr. Rineer is a Fellow of the American Academy Specialist for Implantology (DGI
Slide 24: Company Highlights
Company Highlights Disruptive Formulation & • CXUTM device candidate provides a stable scaffold that supports cellular infiltration, vascularization, and native tissue remodeling1 • Designed to mirror native human ECM, to provide a more supportive environment than collagen alone. "Liquid-to-Gel" Tec
Slide 25: One Formula One Device
One Formula One Device Platform Markets Combined Global TAM ARCHITECTING BIOREGENERATION 1. Ref. Page 5 - TAM
Slide 26: Contact
Contact Conexeu Sciences Inc. Directory Investor Relations Conexeu Sciences Inc. Legal Counsel Auditors IR@conexeu.com 50 West Liberty Street McMillan LLP Adeptus Advisory Group, LLC Suite 880 1055 West Georgia St., #1500 733 State Route 35 +1 (424) 333-5622 | ext. 7 Reno, NV 89501 Vancouver, V6E 4N